These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

475 related items for PubMed ID: 15501959

  • 1. A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia.
    Cooper BW, Veal GJ, Radivoyevitch T, Tilby MJ, Meyerson HJ, Lazarus HM, Koc ON, Creger RJ, Pearson G, Nowell GM, Gosky D, Ingalls ST, Hoppel CL, Gerson SL.
    Clin Cancer Res; 2004 Oct 15; 10(20):6830-9. PubMed ID: 15501959
    [Abstract] [Full Text] [Related]

  • 2. A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia.
    Giles FJ, Cortes JE, Kantarjian HM, O'Brien SM, Estey E, Beran M.
    Leuk Res; 2004 Apr 15; 28(4):353-7. PubMed ID: 15109534
    [Abstract] [Full Text] [Related]

  • 3. Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors.
    Boss DS, Siegel-Lakhai WS, van Egmond-Schoemaker NE, Pluim D, Rosing H, Ten Bokkel Huinink WW, Beijnen JH, Schellens JH.
    Clin Cancer Res; 2009 Jul 01; 15(13):4475-83. PubMed ID: 19531625
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
    Camera A, Rinaldi CR, Palmieri S, Cantore N, Mele G, Mettivier V, Miraglia E, Mastrullo L, Grimaldi F, Luciano L, Guerriero A, Rotoli B, Ferrara F.
    Ann Hematol; 2009 Feb 01; 88(2):151-8. PubMed ID: 18709502
    [Abstract] [Full Text] [Related]

  • 6. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
    Miller AA, Al Omari A, Murry DJ, Case D.
    Lung Cancer; 2006 Dec 01; 54(3):379-85. PubMed ID: 17049403
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia.
    Clavio M, Carrara P, Miglino M, Pierri I, Canepa L, Balleari E, Gatti AM, Cerri R, Celesti L, Vallebella E, Sessarego M, Patrone F, Ghio R, Damasio E, Gobbi M.
    Haematologica; 1996 Dec 01; 81(6):513-20. PubMed ID: 9009438
    [Abstract] [Full Text] [Related]

  • 11. A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma.
    Rose PG, Smrekar M, Haba P, Visser C, Beeler JF.
    Gynecol Oncol; 2005 Dec 01; 99(3):714-9. PubMed ID: 16112177
    [Abstract] [Full Text] [Related]

  • 12. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.
    Seiden MV, Ng SW, Supko JG, Ryan DP, Clark JW, Lynch T, Huang KC, Kwiatkowski D, Skarin A, Eder JP.
    Clin Cancer Res; 2002 Mar 01; 8(3):691-7. PubMed ID: 11895897
    [Abstract] [Full Text] [Related]

  • 13. Phase I trial of paclitaxel, carboplatin, and topotecan with or without filgrastim (granulocyte-colony stimulating factor) in the treatment of patients with advanced, refractory cancer.
    Hainsworth JD, Burris HA, Morrissey LH, Greco FA.
    Cancer; 1999 Mar 01; 85(5):1179-85. PubMed ID: 10091804
    [Abstract] [Full Text] [Related]

  • 14. Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation.
    You Y, Li QB, Chen ZC, Li WM, Xia LH, Zhou H, Zou P.
    Chin Med J (Engl); 2008 Sep 20; 121(18):1770-4. PubMed ID: 19080355
    [Abstract] [Full Text] [Related]

  • 15. Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia.
    Kaufmann SH, Karp JE, Letendre L, Kottke TJ, Safgren S, Greer J, Gojo I, Atherton P, Svingen PA, Loegering DA, Litzow MR, Sloan JA, Reid JM, Ames MM, Adjei AA, Erlichman C.
    Clin Cancer Res; 2005 Sep 15; 11(18):6641-9. PubMed ID: 16166443
    [Abstract] [Full Text] [Related]

  • 16. Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.
    Clavio M, Venturino C, Pierri I, Garrone A, Miglino M, Canepa L, Balleari E, Balocco M, Michelis GL, Ballerini F, Gobbi M.
    Ann Hematol; 2004 Nov 15; 83(11):696-703. PubMed ID: 15322763
    [Abstract] [Full Text] [Related]

  • 17. Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: results of a single-institutional phase II study.
    Kang H, Kim TJ, Lee YY, Choi CH, Lee JW, Bae DS, Kim BG.
    Gynecol Oncol; 2009 Aug 15; 114(2):210-4. PubMed ID: 19446320
    [Abstract] [Full Text] [Related]

  • 18. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
    Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ.
    J Clin Oncol; 2008 Jan 10; 26(2):196-203. PubMed ID: 18182662
    [Abstract] [Full Text] [Related]

  • 19. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
    Gillenwater HH, McCune JS, Lindley C, Faucette S, Shord S, Donahue A, Socinski MA, Stewart CF, Zamboni WC, Kirstein MN, Moore D.
    Cancer Invest; 2005 Jan 10; 23(6):511-9. PubMed ID: 16203659
    [Abstract] [Full Text] [Related]

  • 20. FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia.
    Specchia G, Pastore D, Carluccio P, Liso A, Mestice A, Rizzi R, Ciuffreda L, Pietrantuono G, Liso V.
    Ann Hematol; 2005 Nov 10; 84(12):792-5. PubMed ID: 16047203
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.